Skip to content
MARKETS / NASDAQ / INCR
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Intercure Ltd. INCR

6 fiscal years on record · ILS · FY2024 reported · SEC filings only
ILS 238.8M
▼ 32.8% YoY
ILS -67.8M
ILS -71.3M
In brief

What this company does

InterCure produces and packages bulk cannabis product at its facilities, harvesting the bloomed flower, trimming excess leaves, drying and curing inflorescences, and packaging the processed inflorescences into bulk quantities. It distributes pharmaceutical-grade cannabis products in Israel, using authorized distributors that are IMC-GDP certified, to all of the pharmacies in Israel that are authorized to distribute cannabis products. It has entered into a distribution agreement with a pharmaceutical distributor in Germany. Its current production operations together can produce up to 10 tons per year. Its production system, wholly owned or operated through partnerships, currently consists of two active facilities in Israel, owned and operated by the Company. InterCure has 13 direct subsidiaries.

Written from the business description in Intercure Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 30 April 2026. Every sentence was checked against that document before publication.

Growth
ILS 238.8M
Revenue, FY2024 · full 6-year series below
Revenue ILS M Net income ILS M
FY2024 · Revenue 238.8 · Net income -67.8
200.0M-25.0M-50.0M201920202021202220232024
Compound annual growth
+2.8%
+93.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +93.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−30 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -28.1% · Net -30.5%
5%10%-20%-40%-60%201920202021202220232024
ROE
FY2024 · ROE -15.9%
5%-5%-10%-15%201920202021202220232024

Each ILS of equity lost 16 cents this year.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow ILS M
FY2024 · FCF -71.3
20.0M-25.0M-50.0M201920202021202220232024

Total assetsILS 762.6M
EquityILS 397.0M
CashILS 78.3M
Gross debtILS 183.0M
Net debtILS 104.7M
Current ratio1.73×

Net debt stands at 26% of equity.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · ILS

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202420232022202120202019
Revenue ILS B0.20.40.40.20.10.0
Operating income ILS B−0.1−0.00.10.0−0.0−0.0
EBITDA ILS B······
Income tax ILS B−0.00.00.00.0−0.0−0.0
Net income ILS B−0.1−0.10.00.0−0.0−0.0
Free cash flow ILS B−0.1−0.10.00.0−0.0−0.0
EPS, diluted ILS −1.48−1.360.990.11−1.42−0.25
Dividend / sh ILS ······
Payout %······
ROE %−15.9−13.09.41.3−13.6·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures · 5 divergences in 29 reconciliationsAUDITED

No fiscal year had a computed check that closed clean. 5 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 66 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures5 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image